Biotech · Private company
Aevi Genomic Medicine, LLC, a Cerecor company
Track this companyFree. Adds Aevi Genomic Medicine, LLC, a Cerecor company to your Dealase workspace and tells you when its record changes.
Clinical trials100 recruiting or active
Pipeline programs10From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline10
- NFC-1Phase 3 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
- AEVI-001Phase 2 · Attention Deficit Hyperactivity DisorderClinicalTrials.gov · fetched Nov 12, 2026
- CERC-002Phase 2 · COVID-19 PneumoniaClinicalTrials.gov · fetched Nov 12, 2026
- MDGN201 TARGTEPOPhase 2 · Anemia of End Stage Renal DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1Phase 1 · Attention-deficit Hyperactivity Disorder (ADHD)ClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1Phase 1 · 22q11.2 Deletion SyndromeClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1 100 mgPhase 1 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1 200 mgPhase 1 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1 400 mgPhase 1 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
- NFC-1 800 mgPhase 1 · Attention Deficit Disorder With HyperactivityClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials10
- Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung InjuryPHASE2 · COMPLETED · started Jul 17, 2020ClinicalTrials.gov NCT04412057 · fetched Nov 12, 2026
- PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR MutationsPHASE2 · COMPLETED · started Aug 17, 2018ClinicalTrials.gov NCT03609619 · fetched Nov 12, 2026
- PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR MutationsPHASE2 · COMPLETED · started Aug 28, 2017ClinicalTrials.gov NCT03265119 · fetched Nov 12, 2026
- A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR MutationsCOMPLETED · started Aug 14, 2017ClinicalTrials.gov NCT03233867 · fetched Nov 12, 2026
- Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHDPHASE1 · COMPLETED · started Jan 7, 2017ClinicalTrials.gov NCT03006367 · fetched Nov 12, 2026
- Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric ConditionsPHASE1 · COMPLETED · started Nov 28, 2016ClinicalTrials.gov NCT02895906 · fetched Nov 12, 2026
- Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHDPHASE2_PHASE3 · COMPLETED · started Jun 1, 2016ClinicalTrials.gov NCT02777931 · fetched Nov 12, 2026
- A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHDCOMPLETED · started Feb 1, 2016ClinicalTrials.gov NCT02811211 · fetched Nov 12, 2026
- TARGTEPO Treatment for Anemia in PD US TrialPHASE2 · TERMINATED · started Jun 1, 2015ClinicalTrials.gov NCT02468414 · fetched Nov 12, 2026
- Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity DisorderPHASE1 · COMPLETED · started Jan 1, 2015ClinicalTrials.gov NCT02286817 · fetched Nov 12, 2026